

Teva Pharmaceutical Industries Ltd. (TEVA)

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000818686

Teva Pharmaceutical Industries Ltd. TEVA; healthcare	
Grade	C/D A B C D E on the C/D boundary of 371 graded peers percentile 61.1; sampling error 2.5 points; lower is stronger
Rank	227 of 371
Profitability	C percentile 56.3
Solvency	C percentile 48.3
Growth and financing	C percentile 50.9
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$40.7B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress
Inputs computable	9 of 14
Graded from	filings received through Feb 3, 2026 248 days before the rescan; latest periodic filing 10-Q received Jul 29, 2026
Last close	\$39.22 2026-10-08; market equity \$45.7B
Price used in grade	None



C/D, the tortoise

on the C/D boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: B from Feb 21, 2025, B/C from Mar 21, 2025, D from Feb 21, 2026, C/D from Sep 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 3, 2026

We continue to monitor these legislative developments and evaluate their impacts on us and whether any changes to our business practices and operations are necessary in order to comply with such legislative reforms. However, we cannot accurately predict the ultimate impact of such legislative developments on our business or whether additional changes in regulatory policies will occur in the future. We have experienced, and may continue to experience, delays in launches of our new generic products.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 56.3						
Gross profitability		21.9%	32.2%	60.9	372	2025-12-31
Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		(0.6%)	(6.6%)	79.5	811	2025-12-31
Gross margin stability, five years		1.7 pts	2.8 pts	28.5	243	2025-12-31
Solvency, sleeve percentile 48.3						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(0.41)	(0.31)	38.5	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			required facts have no common fiscal period end
Interest coverage		2.35x	(4.51x)	17.5	81	2025-12-31
Current ratio		1.04x	2.96x	88.8	839	2025-12-31
Growth and financing, sleeve percentile 50.9						
Revenue growth, three-year compound		5.0%	10.0%	60.6	415	2025-12-31
Free cash flow growth, three-year compound		3.3%	10.9%	64.2	96	2025-12-31
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		not computable	2.1%			four consecutive annual observations are required
Net share issuance, one year		1.4%	2.5%	28.0	634	2025-12-31

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
222	Trulieve Cannabis Corp. (TRLV)	59.7	C/D	fortress balance sheet
223	Labcorp Holdings Inc. (LH)	60.0	C/D	
224	Perspective Therapeutics, Inc. (CATX)	60.3	C/D	dilution, fortress balance sheet
225	ARS Pharmaceuticals, Inc. (SPRY)	60.5	C/D	short runway
226	Twist Bioscience Corp. (TWST)	60.8	C/D	fortress balance sheet
227	Teva Pharmaceutical Industries Ltd. (TEVA) <	61.1	C/D	
228	Beam Therapeutics Inc. (BEAM)	61.4	C/D	
229	Akebia Therapeutics, Inc. (AKBA)	61.6	C/D	fortress balance sheet
230	Mannkind Corp. (MNKD)	61.9	C/D	
231	Strata Critical Medical, Inc. (SRTA)	62.2	C/D	short runway, fortress balance sheet
232	Embecta Corp. (EMBC)	62.4	C/D	late filer

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	84.9%	8.0%	85
Distance from 52-week high	(2.4%)	(31.4%)	96
EBIT to enterprise value	3.0%	(1.5%)	67
Free cash flow yield	2.5%	(1.0%)	67
Book value to price	0.17	0.28	36
Sales to price	0.38	0.31	56
Composite equity issuance, five years	6.1%	20.3%	35
Relative strength against the sector, log excess return	0.40	(0.14)	85

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$3.7B
Operating cash flow, four quarters	\$1.9B
Months of runway	not finite
Days since last periodic filing	72 (10-Q received Jul 29, 2026)
Median daily dollar volume, 63 sessions	\$174.2M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$8.9B	2025-12-31	2026-02-03	10-K	0001193125-26-034532

2	assets	us-gaap:Assets	\$40.7B	2025-12-31	2026-02-03	10-K	0001193125-26-034532
3	net income	us-gaap:NetIncomeLoss	\$1.4B	2025-12-31	2026-02-03	10-K	0001193125-26-034532
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.6B	2025-12-31	2026-02-03	10-K	0001193125-26-034532
5	assets	us-gaap:Assets	\$39.3B	2024-12-31	2026-02-03	10-K	0001193125-26-034532
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$17.3B	2025-12-31	2026-02-03	10-K	0001193125-26-034532
7	gross profit	us-gaap:GrossProfit	\$8.1B	2024-12-31	2026-02-03	10-K	0001193125-26-034532
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$16.5B	2024-12-31	2026-02-03	10-K	0001193125-26-034532
9	gross profit	us-gaap:GrossProfit	\$7.6B	2023-12-31	2026-02-03	10-K	0001193125-26-034532
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$15.8B	2023-12-31	2026-02-03	10-K	0001193125-26-034532
11	gross profit	us-gaap:GrossProfit	\$7.0B	2022-12-31	2025-02-05	10-K	0001193125-25-020826
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$14.9B	2022-12-31	2025-02-05	10-K	0001193125-25-020826
13	gross profit	us-gaap:GrossProfit	\$7.6B	2021-12-31	2024-02-12	10-K	0001193125-24-031005
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$15.9B	2021-12-31	2024-02-12	10-K	0001193125-24-031005
15	current assets	us-gaap:AssetsCurrent	\$13.9B	2025-12-31	2026-02-03	10-K	0001193125-26-034532
16	current liabilities	us-gaap:LiabilitiesCurrent	\$13.5B	2025-12-31	2026-02-03	10-K	0001193125-26-034532
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$13.8B	2025-12-31	2026-02-03	10-K	0001193125-26-034532
18	operating income	us-gaap:OperatingIncomeLoss	\$2.2B	2025-12-31	2026-02-03	10-K	0001193125-26-034532
19	book equity	us-gaap:StockholdersEquity	\$7.9B	2025-12-31	2026-02-03	10-K	0001193125-26-034532
20	liabilities	us-gaap:Liabilities	\$32.8B	2025-12-31	2026-02-03	10-K	0001193125-26-034532
21	interest expense	us-gaap:InterestExpense	\$916.0M	2025-12-31	2026-02-03	10-K	0001193125-26-034532
22	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$501.0M	2025-12-31	2026-02-03	10-K	0001193125-26-034532
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.2B	2024-12-31	2026-02-03	10-K	0001193125-26-034532
24	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$498.0M	2024-12-31	2026-02-03	10-K	0001193125-26-034532
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.4B	2023-12-31	2026-02-03	10-K	0001193125-26-034532
26	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$526.0M	2023-12-31	2026-02-03	10-K	0001193125-26-034532
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.6B	2022-12-31	2025-02-05	10-K	0001193125-25-020826
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$548.0M	2022-12-31	2023-02-10	10-K	0001193125-23-031250
29	depreciation amortization	us-gaap:Depreciation	\$421.0M	2025-12-31	2026-02-03	10-K	0001193125-26-034532
30	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	\$11.2B	2025-12-31	2026-02-03	10-K	0001193125-26-034532
31	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$180.0M	2025-12-31	2026-02-03	10-K	0001193125-26-034532
32	current assets	us-gaap:AssetsCurrent	\$12.6B	2024-12-31	2026-02-03	10-K	0001193125-26-034532
33	current liabilities	us-gaap:LiabilitiesCurrent	\$12.8B	2024-12-31	2026-02-03	10-K	0001193125-26-034532
34	assets	us-gaap:Assets	\$43.5B	2023-12-31	2025-02-05	10-K	0001193125-25-020826
35	assets	us-gaap:Assets	\$42.1B	2023-09-30	2024-02-12	10-K	0001193125-24-031005
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,149,812,898	2025-12-31	2026-02-03	10-K	0001193125-26-034532
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,133,838,689	2024-12-31	2025-02-05	10-K	0001193125-25-020826